XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Capital Stock and Stockholders' Deficit (Tables)
3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Summary of Reserved for Issuance Upon the Potential Conversion or Exercise

The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company’s securities as of March 31, 2024, is as follows:

 

Outstanding options to purchase common stock

 

 

3,928,824

 

Restricted Stock Units

 

 

656,016

 

Warrants to purchase preferred stock (as converted to warrants
   to purchase common stock)

 

 

138,857

 

Warrants to purchase common stock

 

 

264,801

 

Public warrants to purchase common stock

 

 

18,759,696

 

Earn-Out Shares

 

 

9,000,000

 

Total

 

 

32,748,194

 

Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding As of March 31, 2024, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified.

 

March 31, 2024

 

Issuance Date

 

Remaining
Contractual Term
(in years)

 

 

Underlying Equity Instrument

 

Balance Sheet
Classification

 

Shares Issuable
Upon Exercise
of Warrant

 

 

Weighted
Average Exercise
Price

 

12/1/2014

 

 

0.7

 

 

Common stock

 

Equity

 

 

44,272

 

 

$

2.44

 

3/30/2021

 

 

7.0

 

 

Common stock

 

Liability

 

 

130,053

 

 

 

6.73

 

9/15/2022

 

 

8.5

 

 

Common stock

 

Liability

 

 

45,238

 

 

 

12.14

 

6/4/2022

 

 

8.2

 

 

Common stock

 

Liability

 

 

45,238

 

 

 

12.14

 

1/17/2017

 

 

2.8

 

 

Common stock

 

Equity

 

 

73,349

 

 

 

0.02

 

8/3/2017

 

 

3.3

 

 

Common stock

 

Equity

 

 

9,779

 

 

 

1.13

 

9/8/2017

 

 

3.4

 

 

Common stock

 

Liability

 

 

28,764

 

 

 

1.05

 

6/19/2018

 

 

4.2

 

 

Common stock

 

Liability

 

 

17,977

 

 

 

1.05

 

6/25/2019

 

 

5.2

 

 

Common stock

 

Liability

 

 

8,988

 

 

 

1.05

 

 

 

 

 

 

 

 

 

 

 

403,658

 

 

 

 

 

 

December 31, 2023

 

Issuance Date

 

Remaining
Contractual Term
(in years)

 

 

Underlying Equity Instrument

 

Balance Sheet
Classification

 

Shares Issuable
Upon Exercise
of Warrant

 

 

Weighted
Average Exercise
Price

 

12/1/2014

 

 

0.9

 

 

Common stock

 

Equity

 

 

44,272

 

 

$

2.44

 

3/30/2021

 

 

7.2

 

 

Common stock

 

Liability

 

 

130,053

 

 

 

6.73

 

9/15/2022

 

 

8.7

 

 

Common stock

 

Liability

 

 

45,238

 

 

 

12.14

 

6/4/2022

 

 

8.4

 

 

Common stock

 

Liability

 

 

45,238

 

 

 

12.14

 

1/17/2017

 

 

3.0

 

 

Common stock

 

Equity

 

 

73,349

 

 

 

0.02

 

8/3/2017

 

 

3.6

 

 

Common stock

 

Equity

 

 

9,779

 

 

 

1.13

 

9/8/2017

 

 

3.7

 

 

Common stock

 

Liability

 

 

28,764

 

 

 

1.05

 

6/19/2018

 

 

4.5

 

 

Common stock

 

Liability

 

 

17,977

 

 

 

1.05

 

6/25/2019

 

 

5.5

 

 

Common stock

 

Liability

 

 

8,988

 

 

 

1.05

 

 

 

 

 

 

 

 

 

 

 

403,658